Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT.

Aswath VenkitaramanArka DeNipun VermaSunita KumariBidyalaxmi LeishangthemRatti Ram SharmaNaveen KalraSandeep GroverVirendra Singh

Published in: Hepatology international (2022)

G-CSF therapy is safe. The improvement in survival at 12 months is not statistically significant. Better control of ascites, improvement of CTP score, fewer encephalopathy episodes and decreased rate of infections were observed with G-CSF therapy (NCT03911037). Trials Registration NCT03911037.

Keyphrases

heart failure
early onset
cerebrospinal fluid
ejection fraction
cell therapy
bone marrow
recombinant human